• 1
    Winhammar JM, Rowe DB, Henderson RD, Kiernan MC. Assessment of disease progression in motor neuron disease. Lancet Neurol. 2005; 4: 22938.
  • 2
    Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009; 8: 94109.
  • 3
    DiBernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in ALS. Biochim. Biophys. Acta 2006; 1762: 11391149.
  • 4
    Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev. Mol. Diagn. 2006; 6: 387398.
  • 5
    Wagner KR. The need for biomarkers in amyotrophic lateral sclerosis drug development. Neurology 2009; 72: 1112.
  • 6
    Kiernan MC, Vucic S, Cheah BC et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 94255.
  • 7
    Lee CD, Song Y, Peltier AC, Jarquin-Valdivia AA, Donofrio PD. Muscle ultrasound quantifies the rate of reduction of muscle thickness in amyotrophic lateral sclerosis. Muscle Nerve 2010; 42: 8149.
  • 8
    Rutkove SB, Zhang H, Schoenfeld DA et al. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin. Neurophysiol. 2007; 118: 24138.
  • 9
    Hashizume A, Katsuno M, Banno H et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 2012; 135: 283848.
  • 10
    Abrahamson M, Olafsson I, Palsdottir A et al. Structure and expression of the human cystatin C gene. Biochem. J. 1990; 268: 287294.
  • 11
    Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR—history, indications, and future research. Clin. Biochem. 2005; 38: 18.
  • 12
    Newman DJ. Cystatin C. Ann. Clin. Biochem. 2002; 39: 89104.
  • 13
    Grubb A, Lo¨fberg H. Human gamma-trace, a basic microprotein: Amino acid sequence and presence in the adenohypophysis. Proc. Natl Acad. Sci. USA 1982; 79: 30247.
  • 14
    Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand. J. Clin. Lab. Invest. 1999; 59: 587592.
  • 15
    Brooks BR, Miller RG, Swash M, Munsat TL. World federation of neurology research group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000; 1: 293299.
  • 16
    Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNFALS Study Group (Phase III). J. Neurol. Sci. 1999; 169: 1321.
  • 17
    Tanaka M, Matsuo K, Enomoto M, Mizuno K. A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin. Biochem. 2004; 37: 2735.
  • 18
    Matsuo S, Imai E, Horio M et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 98292.
  • 19
    Rule A, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentation. Kidney Int. 2006; 69: 399405.
  • 20
    Miller RG, Rosenberg JA, Gelinas DF et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommitte of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 13111323.
  • 21
    Pradat PF, Dubourg O, de Tapia M et al. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener. Dis. 2012; 9: 3852.
  • 22
    Bryan WW, Reisch JS, McDonald G, Herbelin LL, Barohn RJ, Fleckenstein JL. Magnetic resonance imaging of muscle in amyotrophic lateral sclerosis. Neurology 1998; 51: 1103.
  • 23
    Baumgartner RN, Ross R, Heymsfield SB. Does adipose tissue influence bioelectric impedance in obese men and women. J. Appl. Physiol. 1998; 84: 257262.